FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma
Dose optimization data from the Phase 1/2 study to be presented next month at ESMO 2025Second Fast Track designation granted...